The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Official Title: An Open-label, Multicenter, Phase II Clinical Study of HX008 in Combination With Bevacizumab or Lenvatinib in Patients With Advanced Hepatocellular Carcinoma (HCC)
Study ID: NCT04741165
Brief Summary: This is a multi-center,open-label study to evaluate the efficacy and safety of anti-PD-1 antibody HX008 plus bevacizumab or lenvatinib in the first-line treatment of patients with unresectable hepatocellular carcinoma.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The Fist Affiliated Hospital of USTC(Anhui Provincial hospital), Hefei, Anhui, China
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, Beijing, Beijing, China
Cancer Hospital Chinese Academy of Medical Sciences, shenzhen center, Shenzhen, Guangdong, China
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Hunan Provincial People's Hospital, Changsha, Hunan, China
The First Affiliated University of Nanhua University, Hengyang, Hunan, China
The Sixth People's Hospital of Shenyang, Shenyang, Liaoning, China
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Tianjin Cancer Hospital, Tianjin, Tianjin, China
The Central Hospital of Lishui City, Lishui, Zhejiang, China